This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

J. Jankovic, MD

Arch Neurol. 1993;50(3):286-288.

Abstract
• While central nervous system stimulants usually improve attention deficit hyperactivity disorder (ADHD) associated with Tourette's syndrome, they often exacerbate tics and can produce other potentially serious complications. Because deprenyl may have a stimulatory effect and monoamine oxidase inhibitors have been shown to ameliorate hyperactive behavior, we studied this drug in children with the Tourette's syndrome—ADHD combination. Twenty-nine patients, 25 boys and four girls, with a mean age of 11.2 years (range, 6 to 18 years) and duration of symptoms for an average of 6.2 years (range, 1 to 13 years), were enrolled in this open trial after they became refractory to conventional treatments for ADHD. The average duration of treatment with deprenyl was 6.7 months (range, 3 to 15 months) and the average daily dose was 8.1 mg/d (range, 5 to 15 mg/dL). Twenty-six of all patients (90%) reported clinically meaningful improvement in their ADHD (score 2 on a scale of 0 to 4), with the mean global improvement rated at 2.6. There were no serious adverse side effects and only two patients noted exacerbation of their tics. Deprenyl appears to be a safe and effective treatment of ADHD in patients with Tourette's syndrome.

Author Affiliations
From the Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Tex.

Footnotes
Accepted for publication August 28, 1992.

Reprint requests to the Department of Neurology, Baylor College of Medicine, 6550 Fannin, No. 1801, Houston, TX 77030 (Dr Jankovic).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Assessment of Scientific and Ethical Issues in Two Randomized Clinical Trial Designs for Patients With Tourette's Syndrome: A Model for Studies of Multiple Neuropsychiatric Diagnoses
Gilbert and Buncher
J. Neuropsychiatry Clin. Neurosi. 2005;17:324-332.
ABSTRACT | FULL TEXT  

Tourette syndrome, associated conditions and the complexities of treatment
Robertson
Brain 2000;123:425-462.
ABSTRACT | FULL TEXT  

Topical Review: Antidyskinetic Drug Therapy for Pediatric Movement Disorders
Pranzatelli
J Child Neurol 1996;11:355-369.
ABSTRACT  

Neurochemical and some related psychopharmacological aspects of Tourette's syndrome: an update
Baker et al.
J Psychopharmacol 1995;9:273-280.
ABSTRACT